The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.
 
Yvonne Marie Mowery
Employment - Duke Health Private Diagnostic Clinic; UPMC Hillman Cancer Center/University of Pittsburgh
Honoraria - Oakstone; UpToDate
Consulting or Advisory Role - Catalys Pacific
Research Funding - Merck (Inst)
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Mylan; Sanofi
 
Angela M. Hong
Stock and Other Ownership Interests - BeiGene
Consulting or Advisory Role - Roche (I); Telix Pharmaceuticals
Travel, Accommodations, Expenses - Roche (I)
 
Scott Schuetze
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Rain Therapeutics (Inst); Shanghai Pharma (Inst); TRACON Pharma (Inst)
 
Andrew J. Wagner
Consulting or Advisory Role - AADi; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; InhibRx; Lilly; Mundipharma; SERVIER
Research Funding - AADi (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)
 
Varun Monga
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Hutchison MediPharma (Inst); Oblato (Inst); Pfizer (Inst); Prelude Therapeutics (Inst)
Travel, Accommodations, Expenses - Cogent Biosciences
 
Rachel Heise
Employment - CSL Behring (I)
 
Steven Attia
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Guardant Health; Incyte (Inst); InhibRx (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Shanghai Pharma (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Edwin Choy
Consulting or Advisory Role - Adaptimmune; Bayer; Daiichi Sankyo; Epizyme
Research Funding - Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim; Exelixis (Inst); Genentech/Roche; Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); TRACON Pharma (Inst)
 
Melissa Amber Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
Research Funding - Merck
 
Susie Bae
No Relationships to Disclose
 
David Pryor
Speakers' Bureau - AstraZeneca; Bayer
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Gabriel Tinoco
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan; SERVIER
 
Bartosz Chmielowski
Consulting or Advisory Role - Atreca; Delcath Systems; Instil Bio; Novartis; Regeneron; Replimune; SpringWorks Therapeutics; Treeline Biosciences
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); AskGene Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Macrogenics (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - Instil Bio
 
Carolyn R. Freeman
No Relationships to Disclose
 
Matt Van De Rijn
Expert Testimony - Not available
 
Brian E. Brigman
Consulting or Advisory Role - Daiichi Sankyo; Deciphera
Speakers' Bureau - Daiichi Sankyo
(OPTIONAL) Uncompensated Relationships - Medical Board of Advisors Musculoskeletal Transplant Foundation
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; NanoCarrier; SpringWorks Therapeutics
 
David G. Kirsch
Stock and Other Ownership Interests - Lumicell; X-RAD Therapeutics
Consulting or Advisory Role - Lumicell
Research Funding - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - Patent on an imaging device licensed to Lumicell; Patent on small molecule radiosensitizers by XRAD Therapeutics; Royalty on an imaging agent being commercialized by Lumicell